Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05489211 · ClinicalTrials.gov registry record · Phase 2

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase 2 study of Colorectal Cancer and Ovarian Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
454
Enrollment target
20
Study locations

NCT05489211 is a Phase 2 study of Colorectal Cancer and Ovarian Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 454 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05489211, a Phase 2 study of Colorectal Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
454 participants
Enrollment target
20
Study locations

Study Summary

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Conditions Studied

Colorectal Cancer Ovarian Cancer Endometrial Cancer Gastric Cancer Metastatic Castration-Resistant Prostate Cancer Biliary Tract Cancer Urothelial Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Capecitabine
  • DRUG 5-Fluorouracil
  • DRUG Volrustomig
  • DRUG Datopotamab deruxtecan (Dato-DXd)

Study Locations (20)

California

  • Research Site - Los Angeles
  • Research Site - San Diego
  • Research Site - Santa Rosa

Massachusetts

  • Research Site - Boston
  • Research Site - Boston

Ohio

  • Research Site - Cincinnati
  • Research Site - Columbus

Tennessee

  • Research Site - Nashville
  • Research Site - Nashville

Ontario

  • Research Site - Toronto
  • Research Site - Toronto

Indiana

  • Research Site - Muncie

Kansas

  • Research Site - Kansas City

Michigan

  • Research Site - Grand Rapids

Trial Details

FieldValue
Enrollment Target 454 participants
Start Date 2022-09-06
Est. Completion 2027-10-01
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05489211

The ClinicalTrials.gov registry entry for NCT05489211 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (70% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05489211 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Massachusetts, Ohio.

Frequently Asked Questions

What is clinical trial NCT05489211 about?

NCT05489211 is a clinical study titled "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)". TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

What is the current status of trial NCT05489211?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 454 participants. The study started on 2022-09-06. Estimated completion is 2027-10-01.

What conditions does trial NCT05489211 study?

This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT05489211?

The interventions under investigation include: Carboplatin (DRUG), Capecitabine (DRUG), 5-Fluorouracil (DRUG), Volrustomig (DRUG), Datopotamab deruxtecan (Dato-DXd) (DRUG).

Who is sponsoring clinical trial NCT05489211?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05489211 being conducted?

This trial has 20 study locations across California, Indiana, Kansas, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Ovarian Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.